• antibody–drug conjugate
• sacituzumab govitecan
• immune chekpoint inhibitors
• anti-PD-(L)1
• pembrolizumab based treatment
• pembrolizumab alone
• poly ADP-ribose polymerase (PARP) inhibitor
• olaparib
• talazoparib

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)

  Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

color = results color = ROB demonstrated suggested inconclusive safety concern ongoing study not assessable low moderate serious ongoing study display ongoing demontrated benefit only